In our study, ZFAS1 was found to be significantly upregulated in DN blood samples, and also in HG-induced cells, which suggest that the ZFAS1 could serve as an effective biomarker or potential therapeutic target for treating DN. The gene discussed is ZFAS1; the disease is liver dysplastic nodule.